LEXX

+ Watchlist + Portfolio

Lexaria Bioscience Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $11.73
52-Week Range: $4.21 – $23.25
Market Cap: $18.62M
P/E (TTM): —
EPS (TTM): -5.04
Dividend Yield: —

Advanced Metrics

Price/Book: 3.93
PEG Ratio: —
Return on Equity: -162.77%
Return on Assets: -81.30%
Gross Margin: 100.00%
Operating Margin: -3862.94%
Profit Margin: 0.00%
Current Ratio: 10.60
Debt/Equity: 0.02
Total Debt: $86.71K
Free Cash Flow: $-4.69M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $14.70M

LEXX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$255.40K	$226.21K	$464.28K	$705.92K
Cost of Revenue	$71.84K	$31.50K	$4.82K	$2.72K
Gross Profit	$183.56K	$194.71K	$459.46K	$703.20K
Research & Development	$1.84M	$3.67M	$2.36M	$8.24M
Selling, General & Admin	$4.96M	$3.06M	$3.85M	$4.35M
Operating Expenses	$6.80M	$6.73M	$6.21M	$12.58M
Operating Income	-$6.62M	-$6.53M	-$5.75M	-$11.88M
EBITDA	-$6.52M	-$6.39M	-$5.68M	-$11.79M
Pretax Income	-$7.38M	-$6.71M	-$5.81M	-$11.91M
Net Income	-$7.27M	-$6.66M	-$5.80M	-$11.90M
Diluted EPS	-1.24	-1.01	-0.47	-0.66
Diluted Shares	5.89M	6.61M	12.38M	18.00M

LEXX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.81M	$1.35M	$6.50M	$1.80M
Receivables	$201.78K	$126.69K	$154.48K	$368.36K
Inventory	$38.42K	$0.00	—	—
Current Assets	$6.98M	$2.15M	$7.90M	$3.47M
Total Assets	$7.83M	$3.08M	$8.87M	$4.18M
Current Liabilities	$194.04K	$267.74K	$1.10M	$1.49M
Total Debt	$49.99K	$163.97K	$137.37K	$109.32K
Total Liabilities	$201.44K	$403.91K	$1.21M	$1.57M
Retained Earnings	-$39.10M	-$45.76M	-$51.56M	-$63.46M
Shareholders' Equity	$7.95M	$3.04M	$8.04M	$2.99M
Working Capital	$6.78M	$1.88M	$6.80M	$1.97M

LEXX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$4.88M	-$5.88M	-$4.96M	-$10.45M
Capital Expenditure	-$180.64K	-$169.61K	-$188.60K	-$99.75K
Free Cash Flow	-$5.06M	-$6.05M	-$5.15M	-$10.55M
Depreciation & Amortisation	$102.72K	$145.40K	$76.15K	$87.83K
Stock-Based Compensation	$752.59K	$170.38K	$492.24K	$859.49K
Investing Cash Flow	-$180.64K	-$169.61K	-$188.60K	-$243.02K
Financing Cash Flow	-$44.60K	$1.59M	$10.32M	$6.05M
Net Change in Cash	-$5.10M	-$4.46M	$5.17M	-$4.65M

LEXX Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$174.00K	$174.00K	$0.00	$20.00K	—
Cost of Revenue	$0.00	$0.00	$0.00	$0.00	—
Gross Profit	$174.00K	$174.00K	$0.00	$20.00K	—
Research & Development	$2.72M	$1.88M	$671.34K	$475.39K	—
Selling, General & Admin	$1.21M	$980.48K	$902.29K	$996.51K	—
Operating Expenses	$3.92M	$2.86M	$1.57M	$1.47M	—
Operating Income	-$3.75M	-$2.69M	-$1.57M	-$1.45M	—
EBITDA	-$3.72M	-$2.67M	-$1.56M	-$1.43M	—
Pretax Income	-$3.79M	-$2.70M	-$1.60M	-$1.45M	—
Income Tax	—	—	$1.79K	$2.60K	—
Net Income	-$3.79M	-$2.70M	-$1.60M	-$1.45M	—
Diluted EPS	-0.21	—	-0.07	-0.06	-0.08
Diluted Shares	18.30M	—	21.38M	24.44M	24.81M

LEXX Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$6.47M	$4.59M	$1.80M	$4.28M	$5.13M
Receivables	$331.17K	$358.13K	$368.36K	$88.04K	$42.03K
Current Assets	$7.72M	$5.81M	$3.47M	$5.36M	$5.77M
Total Assets	$8.68M	$6.74M	$4.18M	$6.05M	$6.49M
Current Liabilities	$1.82M	$1.49M	$1.49M	$1.46M	$214.67K
Total Debt	$123.72K	$116.59K	$109.32K	$101.92K	$94.39K
Total Liabilities	$1.92M	$1.57M	$1.57M	$1.53M	$277.00K
Retained Earnings	-$56.98M	-$60.76M	-$63.46M	-$65.06M	-$66.51M
Shareholders' Equity	$7.14M	$5.55M	$2.99M	$4.91M	$6.60M
Working Capital	$5.90M	$4.32M	$1.97M	$3.91M	$5.56M

LEXX Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.50M	-$3.58M	-$2.64M	-$984.10K	-$2.16M
Capital Expenditure	-$27.89K	-$19.44K	-$14.61K	-$5.10K	-$55.91K
Free Cash Flow	-$1.53M	-$3.60M	-$2.66M	-$989.20K	-$2.22M
Depreciation & Amortisation	$2.28K	$30.95K	$21.40K	$16.87K	$19.10K
Stock-Based Compensation	$167.22K	$470.14K	$122.72K	$74.89K	$74.89K
Investing Cash Flow	-$27.89K	-$19.44K	-$157.88K	-$5.10K	-$53.91K
Financing Cash Flow	$11.72K	$1.69M	$0.00	$3.47M	$3.04M
Net Change in Cash	-$1.51M	-$1.91M	-$2.80M	$2.48M	$826.27K

Market Snapshot

About

Lexaria Bioscience Corp. is a biotechnology company focused on drug delivery technology. The company has developed and patents DehydraTECH, a drug delivery platform designed to improve the way active pharmaceutical ingredients enter the bloodstream. Lexaria's technology aims to enhance bioavailability, reduce time of onset, and mask unwanted tastes for orally administered bioactive compounds.